Melanoma: immune checkpoint blockade story gets better
Mené sur 173 patients atteints d'un mélanome avancé réfractaire à l'ipilimumab (durée médiane de suivi : 8 mois), cet essai de phase I évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité du pembrolizumab, un anticorps monoclonal anti PD-1
The 10-year survival for patients with metastatic melanoma is less than 10%. After decades of failed attempts to improve treatment outcomes in patients with this disease, the recent successes with ipilimumab and the inhibitors of BRAF and MEK (vemurafenib, dabrafenib, and trametinib) have ushered in a new era in systemic therapy. These breakthroughs have not only provided more treatment options for patients with melanoma, but have also spurred the investigation of a new generation of drugs for ...
The Lancet , commentaire, 2013